Gene therapy for lysosomal storage disorders: a good start.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Human Molecular Genetics

• Publication date

  2016-04-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/hmg/ddv457PMID 26604151
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Parkinson's disease].

  2022cited by this paper
• Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States.

  2016cited by this paper
• Combined gene/cell therapies provide long-term and pervasive rescue of multiple pathological symptoms in a murine model of globoid cell leukodystrophy

  2015cited by this paper
• Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study.

  2015cited by this paper
• Intravenous injection of AAVrh10-GALC after the neonatal period in twitcher mice results in significant expression in the central and peripheral nervous systems and improvement of clinical features.

  2015cited by this paper
• Mechanism-Based Combination Treatment Dramatically Increases Therapeutic Efficacy in Murine Globoid Cell Leukodystrophy

  2015cited by this paper
• Systemic AAV9 gene transfer in adult GM1 gangliosidosis mice reduces lysosomal storage in CNS and extends lifespan.

  2015cited by this paper
• Hematopoietic Stem Cell Gene Therapy Corrects Neuropathic Phenotype in Murine Model of Mucopolysaccharidosis Type II

  2015influential reference
• Intracerebral Gene Therapy Using AAVrh.10-hARSA Recombinant Vector to Treat Patients with Early-Onset Forms of Metachromatic Leukodystrophy: Preclinical Feasibility and Safety Assessments in Nonhuman Primates

  2015cited by this paper
• Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines.

  2015cited by this paper
• Arylsulfatase A Overexpressing Human iPSC-derived Neural Cells Reduce CNS Sulfatide Storage in a Mouse Model of Metachromatic Leukodystrophy.

  2015cited by this paper
• In vivo genome editing of the albumin locus as a platform for protein replacement therapy.

  2015cited by this paper
• Neonatal Systemic AAV Induces Tolerance to CNS Gene Therapy in MPS I Dogs and Nonhuman Primates.

  2015cited by this paper
• Early Umbilical Cord Blood-Derived Stem Cell Transplantation Does Not Prevent Neurological Deterioration in Mucopolysaccharidosis Type III.

  2015cited by this paper
• Lysosomal storage diseases: from pathophysiology to therapy.

  2015influential reference
• A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II

  2015cited by this paper
• Enzyme enhancers for the treatment of Fabry and Pompe disease.

  2015cited by this paper
• AAV gene transfer delays disease onset in a TPP1-deficient canine model of the late infantile form of Batten disease

  2015cited by this paper
• Neuronopathic lysosomal storage disorders: Approaches to treat the central nervous system.

  2015cited by this paper
• Biochemical, histological and functional correction of mucopolysaccharidosis type IIIB by intra-cerebrospinal fluid gene therapy.

  2015cited by this paper
• Ex Vivo Gene Therapy Using Patient iPSC-Derived NSCs Reverses Pathology in the Brain of a Homologous Mouse Model

  2015cited by this paper
• Outcomes after hematopoietic stem cell transplantation for children with I-cell disease.

  2014cited by this paper
• Intracerebral Administration of Adeno-Associated Viral Vector Serotype rh.10 Carrying Human SGSH and SUMF1 cDNAs in Children with Mucopolysaccharidosis Type IIIA Disease: Results of a Phase I/II Trial

  2014cited by this paper
• Insulin Receptor Antibody–Sulfamidase Fusion Protein Penetrates the Primate Blood–Brain Barrier and Reduces Glycosoaminoglycans in Sanfilippo Type A Cells

  2014cited by this paper
• Hematopoietic SCT: a useful treatment for late metachromatic leukodystrophy

  2014cited by this paper
• Comparison of Five Peptide Vectors for Improved Brain Delivery of the Lysosomal Enzyme Arylsulfatase A

  2014cited by this paper
• Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB

  2014cited by this paper
• The Pharmacological Chaperone AT2220 Increases the Specific Activity and Lysosomal Delivery of Mutant Acid Alpha-Glucosidase, and Promotes Glycogen Reduction in a Transgenic Mouse Model of Pompe Disease

  2014cited by this paper
• Similar Therapeutic Efficacy Between a Single Administration of Gene Therapy and Multiple Administrations of Recombinant Enzyme in a Mouse Model of Lysosomal Storage Disease

  2014cited by this paper
• Gene Therapy for Mucopolysaccharidosis Type VI Is Effective in Cats Without Pre-Existing Immunity to AAV8

  2013cited by this paper
• Multipotent Stromal Cells Alleviate Inflammation, Neuropathology, and Symptoms Associated with Globoid Cell Leukodystrophy in the Twitcher Mouse

  2013cited by this paper
• Hematopoietic stem cell gene therapy for the multisystemic lysosomal storage disorder cystinosis.

  2013cited by this paper
• Scientific category: CHEMOKINES Chemokine-induced recruitment of genetically modified bone marrow cells into the CNS of GM1-gangliosidosis mice corrects neuronal pathology

  2013cited by this paper
• Pharmacological chaperones for enzyme enhancement therapy in genetic diseases.

  2013cited by this paper
• Therapeutic approaches for lysosomal storage diseases: a patent update.

  2013cited by this paper
• Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy.

  2013cited by this paper
• Enzyme replacement therapy and substrate reduction therapy in lysosomal storage disorders with neurological expression.

  2013cited by this paper
• Myeloid/Microglial Driven Autologous Hematopoietic Stem Cell Gene Therapy Corrects a Neuronopathic Lysosomal Disease

  2013cited by this paper
• Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis.

  2013cited by this paper
• Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning.

  2013cited by this paper
• The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease

  2012cited by this paper
• Bone marrow transplantation increases efficacy of central nervous system-directed enzyme replacement therapy in the murine model of globoid cell leukodystrophy.

  2012cited by this paper
• Hematopoietic Stem Cell and Gene Therapy Corrects Primary Neuropathology and Behavior in Mucopolysaccharidosis IIIA Mice.

  2012cited by this paper
• Allogeneic hematopoietic SCT for alpha-mannosidosis: an analysis of 17 patients

  2012cited by this paper
• Developmental and functional outcomes in children with a positive newborn screen for Krabbe disease: a pilot study of a phone-based interview surveillance technique.

  2012influential reference
• Long-Term Follow-Up After Gene Therapy for Canavan Disease

  2012cited by this paper
• Correction of Pathological Accumulation of Glycosaminoglycans in Central Nervous System and Peripheral Tissues of MPSIIIA Mice Through Systemic AAV9 Gene Transfer

  2012cited by this paper
• Brain conditioning is instrumental for successful microglia reconstitution following hematopoietic stem cell transplantation

  2012cited by this paper
• Neural Stem Cell Gene Therapy Ameliorates Pathology and Function in a Mouse Model of Globoid Cell Leukodystrophy

  2011cited by this paper
• Recent developments in therapeutic approaches for lysosomal storage diseases.

  2011cited by this paper
• Clinical outcomes following hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis VI.

  2011cited by this paper
• Leukodystrophy and gene therapy with a dimmer switch.

  2011cited by this paper
• CNS-targeted AAV5 gene transfer results in global dispersal of vector and prevention of morphological and function deterioration in CNS of globoid cell leukodystrophy mouse model.

  2011cited by this paper
• Pathophysiology of neuropathic lysosomal storage disorders

  2010cited by this paper
• Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model.

  2010cited by this paper
• The galactocerebrosidase enzyme contributes to the maintenance of a functional hematopoietic stem cell niche.

  2010cited by this paper
• Identification of Hematopoietic Stem Cell–Specific miRNAs Enables Gene Therapy of Globoid Cell Leukodystrophy

  2010cited by this paper
• Current international perspectives on hematopoietic stem cell transplantation for inherited metabolic disorders.

  2010cited by this paper
• Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the Pompe disease phenotype.

  2010cited by this paper
• Widespread enzymatic correction of CNS tissues by a single intracerebral injection of therapeutic lentiviral vector in leukodystrophy mouse models.

  2010cited by this paper
• Neural Stem Cell Transplantation Benefits a Monogenic Neurometabolic Disorder During the Symptomatic Phase of Disease

  2009cited by this paper
• Diseases of the Nervous System in Childhood

  2009cited by this paper
• Multipotential Neural Precursors Transplanted into the Metachromatic Leukodystrophy Brain Fail to Generate Oligodendrocytes but Contribute to Limit Brain Dysfunction

  2008cited by this paper
• Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis by CNS Administration of a Serotype 2 Adeno-Associated Virus Expressing CLN2 cDNA

  2008cited by this paper
• Central nervous system therapy for lysosomal storage disorders.

  2008influential reference
• Effect of neonatal administration of a retroviral vector expressing alpha-L-iduronidase upon lysosomal storage in brain and other organs in mucopolysaccharidosis I mice.

  2007cited by this paper
• Improvements in mucopolysaccharidosis I mice after adult retroviral vector-mediated gene therapy with immunomodulation.

  2007cited by this paper
• Single‐dose intracerebroventricular administration of galactocerebrosidase improves survival in a mouse model of globoid cell leukodystrophy

  2007cited by this paper
• Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions

  2007cited by this paper
• Central nervous system-directed AAV2/5-mediated gene therapy synergizes with bone marrow transplantation in the murine model of globoid-cell leukodystrophy.

  2007cited by this paper
• Partial cure of established disease in an animal model of metachromatic leukodystrophy after intracerebral adeno-associated virus-mediated gene transfer

  2007cited by this paper
• Multiple reduced-intensity conditioning regimens facilitate correction of Fabry mice after transplantation of transduced cells.

  2007cited by this paper
• Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease

  2007cited by this paper
• Local self-renewal can sustain CNS microglia maintenance and function throughout adult life

  2007cited by this paper
• Early and Rapid Engraftment of Bone Marrow-Derived Microglia in Scrapie

  2006cited by this paper
• Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice.

  2006cited by this paper
• The therapeutic potential of neural stem/progenitor cells in murine globoid cell leukodystrophy is conditioned by macrophage/microglia activation.

  2006cited by this paper
• Gene therapy of the brain in the dog model of Hurler's syndrome

  2006cited by this paper
• Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease.

  2006cited by this paper
• Oligodendroglial Progenitor Cell Therapy Limits Central Neurological Deficits in Mice with Metachromatic Leukodystrophy

  2006cited by this paper
• Intracerebral adeno-associated virus-mediated gene transfer in rapidly progressive forms of metachromatic leukodystrophy.

  2006cited by this paper
• Miglustat: substrate reduction therapy for glycosphingolipid lysosomal storage disorders.

  2006cited by this paper
• Histopathological and behavioral improvement of murine mucopolysaccharidosis type VII by intracerebral transplantation of neural stem cells.

  2006cited by this paper
• Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease.

  2005influential reference
• Liver-directed neonatal gene therapy prevents cardiac, bone, ear, and eye disease in mucopolysaccharidosis I mice.

  2005cited by this paper
• Functional Correction of CNS Phenotypes in a Lysosomal Storage Disease Model Using Adeno-Associated Virus Type 4 Vectors

  2005cited by this paper
• Axons mediate the distribution of arylsulfatase A within the mouse hippocampus upon gene delivery.

  2005cited by this paper
• Bone marrow-derived microglia contribute to the neuroinflammatory response and express iNOS in the MPTP mouse model of Parkinson's disease.

  2005cited by this paper
• Invasion of Hematopoietic Cells into the Brain of Amyloid Precursor Protein Transgenic Mice

  2005cited by this paper
• Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice.

  2005cited by this paper
• AAV2/5 vector expressing galactocerebrosidase ameliorates CNS disease in the murine model of globoid-cell leukodystrophy more efficiently than AAV2.

  2005cited by this paper
• Neonatal retroviral vector-mediated hepatic gene therapy reduces bone, joint, and cartilage disease in mucopolysaccharidosis VII mice and dogs.

  2004cited by this paper
• Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells.

  2004cited by this paper
• Cord-blood transplants from unrelated donors in patients with Hurler's syndrome.

  2004influential reference
• Blood to brain to the rescue.

  2004cited by this paper
• Improved Behavior and Neuropathology in the Mouse Model of Sanfilippo Type IIIB Disease after Adeno-Associated Virus-Mediated Gene Transfer in the Striatum

  2004cited by this paper
• Administration of a Replication-Deficient Adeno-Associated Virus Gene Transfer Vector Expressing the Human CLN2 cDNA to the Brain of Children with Late Infantile Neuronal Ceroid Lipofuscinosis

  2004cited by this paper
• Globoid Cell Leukodystrophy (Krabbe's Disease): Update

  2003cited by this paper
• Gaucher disease and the clinical experience with substrate reduction therapy.

  2003cited by this paper
• [Lysosomal disease].

  2003cited by this paper

• The delivery challenge of adeno-associated virus vector-based gene therapies for neurological diseases

  2026cites this paper
• Gene editing for Spinocerebellar ataxia type 3 taking advantage of the human ATXN3L paralog as replacement gene

  2025cites this paper
• Choroid plexus-targeted viral gene therapy for alpha-mannosidosis, a prototypical neurometabolic lysosomal storage disease

  2025cites this paper
• Reduction of Neuroinflammation and Seizures in a Mouse Model of CLN1 Batten Disease using the Small Molecule Enzyme Mimetic, N-Tert-Butyl Hydroxylamine

  2024cites this paper
• Donor bone marrow–derived macrophage engraftment into the central nervous system of patients following allogeneic transplantion

  2023cites this paper
• Donor Bone Marrow Derived Macrophage Engraftment into the Central Nervous System of Allogeneic Transplant Patients

  2023cites this paper
• Glial Dysfunction and Its Contribution to the Pathogenesis of the Neuronal Ceroid Lipofuscinoses

  2022cites this paper
• Phenotypic Correction of Murine Mucopolysaccharidosis Type II by Engraftment of Ex Vivo Lentiviral Vector-Transduced Hematopoietic Stem and Progenitor Cells

  2022cites this paper
• How much energy is needed to keep the stored cellular mass and energy free of errors: Case studies

  2022cites this paper
• Gene Therapy for Pediatric Neurologic Disease.

  2022cites this paper
• Efficient CRISPR/Cas9 nickase-mediated genome editing in an in vitro model of mucopolysaccharidosis IVA

  2022cites this paper
• Comprehensive Review of Stem Cell Research: Current Status and Future Perspectives

  2022cites this paper
• Pharmacological Chaperones for β‐Galactosidase Related to GM1‐Gangliosidosis and Morquio B: Recent Advances

  2021cites this paper
• Dosage Compensation in Females with X-Linked Metabolic Disorders

  2021cites this paper
• GM2 Gangliosidosis: Clinical Features and Current Therapies

  2020cites this paper
• Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment

  2020cites this paper
• The potential of gene therapy for mucopolysaccharidosis type I

  2020cites this paper
• Exploiting toxin internalization receptors to enhance delivery of proteins to lysosomes for enzyme replacement therapy

  2020cites this paper
• Gene Therapy Targeting the Inner Retina Rescues the Retinal Phenotype in a Mouse Model of CLN3 Batten Disease

  2020cites this paper
• GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies

  2020cites this paper
• Mechanistic Insights into the Chaperoning of Human Lysosomal-Galactosidase Activity: Highly Functionalized Aminocyclopentanes and C-5a-Substituted Derivatives of 4-epi-Isofagomine

  2020cites this paper
• Human iPSC-Based Models for the Development of Therapeutics Targeting Neurodegenerative Lysosomal Storage Diseases

  2020cites this paper
• Systemic Treatment of Fabry Disease Using a Novel AAV9 Vector Expressing α-Galactosidase A

  2020cites this paper
• Exploiting the diphtheria toxin internalization receptor enhances delivery of proteins to lysosomes for enzyme replacement therapy

  2020cites this paper
• Galactosialidosis: preclinical enzyme replacement therapy in a mouse model of the disease, a proof of concept

  2020cites this paper
• Mukopolysaccharidosen

  2020cites this paper
• Neonatal brain-directed gene therapy rescues a mouse model of neurodegenerative CLN6 Batten disease

  2019cites this paper
• Positron Emission Tomography in Pediatric Neurodegenerative Disorders.

  2019cites this paper
• Mukopolysaccharidosen

  2019cites this paper
• Less is more: the efficacy of gene therapy to treat Fabry disease

  2018cites this paper
• Human iPSC-based models highlight defective glial and neuronal differentiation from neural progenitor cells in metachromatic leukodystrophy

  2018cites this paper
• Metallothioneins are neuroprotective agents in lysosomal storage disorders

  2018cites this paper
• Human iPSC-based models highlight defective glial and neuronal differentiation from neural progenitor cells in metachromatic leukodystrophy

  2018cites this paper
• Newborn Screening for Lysosomal Disease: Mission Creep and a Taste of Things to Come?

  2018cites this paper
• New Approaches to Tay-Sachs Disease Therapy

  2018cites this paper
• Cryo-EM Structures of the Human Endolysosomal TRPML3 Channel in Three Distinct States

  2017cites this paper
• Ten plus one challenges in diseases of the lysosomal system.

  2017cites this paper
• Emptying the stores: lysosomal diseases and therapeutic strategies

  2017cites this paper
• Novel Delivery Strategies

  2017cites this paper
• N-Substituted 5-amino-1-hydroxymethyl-cyclopentanetriols: A new family of activity promotors for a GM1-gangliosidosis related human lysosomal β-galactosidase mutant.

  2017cites this paper
• Involvement of the lysosomal protein NPC1 in the pathogenesis of Huntington's disease

  2017cites this paper
• Clinical Gene Therapy for Neurodegenerative Diseases: Past, Present, and Future

  2017cites this paper
• Presentation and treatments for Mucopolysaccharidosis Type II (MPS II; Hunter Syndrome)

  2017cites this paper
• Impact of lysosome status on extracellular vesicle content and release.

  2016cites this paper
• Overcoming Toxicity from Transgene Overexpression Through Vector Design in AAV Gene Therapy for GM2 Gangliosidoses

  2016cites this paper
• Origins of Brain Tumor Macrophages.

  2016cites this paper
• Biomarkers in Lysosomal Storage Diseases

  2016cites this paper
• Alterations in membrane trafficking and pathophysiological implications in lysosomal storage disorders.

  2016cites this paper
• Low-dose Gene Therapy Reduces the Frequency of Enzyme Replacement Therapy in a Mouse Model of Lysosomal Storage Disease

  2016cites this paper
• Glycosphingolipid analysis in a naturally occurring ovine model of acute neuronopathic Gaucher disease.

  2016cites this paper
• Perspective on innovative therapies for globoid cell leukodystrophy

  2016influential citation
• Biomarkers in Lysosomal Storage Diseases

  2016cites this paper
• Development of gene therapy for Niemann-Pick Type C disease

  2015influential citation